Shots: The P-IIIb Liberty study involves assessing of Aimovig (140 mg) vs PBO @12 wks. in patients with episodic migraine (4 to 14 migraine days/month) P-IIIb LIBERTY study results: reduction in migrane days 50% @1EP (30% vs 14%); reduction in migrane days 75% @2EP (12% vs 4%); migrane free patients 6%; MMD (1.8 vs 0.2) […]Read More
Tags : P-IIIb LIBERTY study’s
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US